Journal of Cancer Research and Therapeutics Close
 

Figure 3: Ductal carcinoma in situ component of infiltrating duct carcinoma: (a-c) estrogen receptor, progesterone receptor, and HER2 immunostaining show uniformly positive tumor cells in in situ and invasive component (estrogen receptor and progesterone receptor immunostain). (d) CK8/18 shows strong cytoplasmic and membranous positivity in tumor epithelial cells in in situ and invasive component (CK8/18 immunostain), (e) CK14 immunostain shows strong cytoplasmic and membranous positivity in > 10% of tumor epithelial cells in ductal carcinoma in situ component only (CK14 immunostain), and (f) negative CK5/6 in ductal carcinoma in situ and invasive component (CK5/6 immunostain)

Figure 3: Ductal carcinoma <i>in situ</i> component of infiltrating duct carcinoma: (a-c) estrogen receptor, progesterone receptor, and HER2 immunostaining show uniformly positive tumor cells in <i>in situ</i> and invasive component (estrogen receptor and progesterone receptor immunostain). (d) CK8/18 shows strong cytoplasmic and membranous positivity in tumor epithelial cells in <i>in situ</i> and invasive component (CK8/18 immunostain), (e) CK14 immunostain shows strong cytoplasmic and membranous positivity in > 10% of tumor epithelial cells in ductal carcinoma <i>in situ</i> component only (CK14 immunostain), and (f) negative CK5/6 in ductal carcinoma <i>in situ</i> and invasive component (CK5/6 immunostain)